Hereditary Angioedema

The FDA has granted priority review to a supplemental biologics license application for the potential expanded use of lanadelumab-flyo to prevent hereditary angioedema attacks in patients aged 2 to younger than 12 years.

Prader-Willi syndrome can delay the diagnosis of hereditary angioedema, which already can be difficult to identify, according to a case report published in Annals of Allergy, Asthma & Immunology.

Lanadelumab prevented hereditary angioedema attacks among patients aged 2 to younger than 12 years with no serious adverse events, according to a study presented at European Academy of Allergy and Clinical Immunology Hybrid Congress.

Long-term subcutaneous treatment with a C1 inhibitor decreased the frequency and severity of hereditary angioedema attacks as well as the use of on-demand medications, according to a study published in Allergy and Asthma Proceedings.

In this video, Douglas Jones, MD, Director of Rocky Mountain Allergy at Tanner Clinic, discusses the major unmet needs in the treatment of hereditary angioedema.

In this video, Douglas Jones, MD, Directory of Rocky Mountain Allergy at Tanner Clinic, discusses the current state of the pipeline for hereditary angioedema treatment.

In this video, Douglas Jones, MD, Director of Rocky Mountain Allergy at Tanner Clinic, discusses how he approaches putting together treatment plans for hereditary angioedema patients, and how understanding patients' individual situation is a major key.

In this video, Douglas Jones, MD, Director of Rocky Mountain Allergy at Tanner Clinic, discusses how he approaches managing quality of life for hereditary angioedema patients.

In these videos, Marc Riedl, MD, an allergist/immunologist at UC San Diego Health, discusses promising new treatments for hereditary angioedema.

In these videos, Marc Riedl, MD, an allergist/immunologist at UC San Diego Health, discusses care disparities that exist for patients with HAE.